Ewer M - Search Results

1

NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension.

Kilbourn RG, Fonseca GA, Griffith OW, Ewer M, Price K, Striegel A, Jones E, Logothetis CJ. Kilbourn RG, et al. Among authors: ewer m. Crit Care Med. 1995 Jun;23(6):1018-24. doi: 10.1097/00003246-199506000-00005. Crit Care Med. 1995. PMID: 7774211 Clinical Trial.

2

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.

Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Valero V, et al. Among authors: ewer m. J Clin Oncol. 1999 May;17(5):1425-34. doi: 10.1200/JCO.1999.17.5.1425. J Clin Oncol. 1999. PMID: 10334527 Clinical Trial.

3

Critical cardiologic considerations in the cancer patient.

Ewer MS, Ali MK. Ewer MS, et al. Crit Care Clin. 1988 Jan;4(1):41-60. Crit Care Clin. 1988. PMID: 3061579 Review.

4

Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck.

Shin DM, Kramer AM, Dimery IW, Raber MN, Ewer M, Hong WK. Shin DM, et al. Among authors: ewer m. Invest New Drugs. 1991 Feb;9(1):89-91. doi: 10.1007/BF00194554. Invest New Drugs. 1991. PMID: 2026488 Clinical Trial.

5

Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.

Umsawasdi T, Valdivieso M, Booser DJ, Barkley HT Jr, Ewer M, MacKay B, Dhingra HM, Murphy WK, Spitzer G, Chiuten DF, et al. Umsawasdi T, et al. Among authors: ewer m. Cancer. 1989 Nov 15;64(10):1995-2000. doi: 10.1002/1097-0142(19891115)64:10<1995::aid-cncr2820641004>3.0.co;2-l. Cancer. 1989. PMID: 2553235 Clinical Trial.

6

Nodus migrans: the case of the migrating knot.

Ewer MS, Ali MK, Gibbs HR, Swafford J. Ewer MS, et al. Am J Crit Care. 1992 Sep;1(2):108-10. Am J Crit Care. 1992. PMID: 1339173

7

A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.

Hortobagyi GN, Yap HY, Kau SW, Fraschini G, Ewer MS, Chawla SP, Benjamin RS. Hortobagyi GN, et al. Among authors: ewer ms. Am J Clin Oncol. 1989 Feb;12(1):57-62. doi: 10.1097/00000421-198902000-00014. Am J Clin Oncol. 1989. PMID: 2643296 Clinical Trial.

8

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.

Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B, et al. Hortobagyi GN, et al. Among authors: ewer ms. Cancer. 1989 Jan 1;63(1):37-45. doi: 10.1002/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-z. Cancer. 1989. PMID: 2910423

9

Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.

Ewer MS, Jaffe N, Ried H, Zietz HA, Benjamin RS. Ewer MS, et al. Med Pediatr Oncol. 1998 Dec;31(6):512-5. doi: 10.1002/(sici)1096-911x(199812)31:6<512::aid-mpo8>3.0.co;2-4. Med Pediatr Oncol. 1998. PMID: 9835904

10

Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.

Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU. Ibrahim NK, et al. Among authors: ewer m. Cancer Chemother Pharmacol. 1999;43(6):471-8. doi: 10.1007/s002800050926. Cancer Chemother Pharmacol. 1999. PMID: 10321507

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

142 results

Search Page